Karl Kramer

Karl Kramer

Auto-generated profile, based on publicly available information

Karl Kramer

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2023 in Science
Verified
Journal Article
Closed access
JZJana Zecha
Jana Zecha
FBFlorian P. Bayer
Florian P. Bayer
SWSvenja Wiechmann
Svenja Wiechmann
JWJulia Woortman
Julia Woortman
NBNicola Berner
Nicola Berner
BKBernhard Kuster
Bernhard Kuster
Although most cancer drugs modulate the activities of cellular pathways by changing posttranslational modifications (PTMs), little is known regarding the extent and the time- and dose-response characteristics of drug-regulated PTMs. In this work, we introduce a proteomic assay called decryptM that quantifies drug-PTM modulation for thousands of PTMs in cells to shed light on target engagement and drug mechanism of action. Examples range from detecting DNA damage by chemotherapeutics, to identifying drug-specific PTM signatures of kinase inhibitors, to demonstrating that rituximab kills CD20-positive B cells by overactivating B cell receptor signaling. DecryptM profiling of 31 cancer drugs in 13 cell lines demonstrates the broad applicability of the approach. The resulting 1.8 million dose-response curves are provided as an interactive molecular resource in ProteomicsDB.

7 May 2024 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
SEStephan Eckert
Stephan Eckert
NBNicola Berner
Nicola Berner
KKKarl Kramer
Karl Kramer
ASAnnika Schneider
Annika Schneider
JMJulian Müller
Julian Müller
BKBernhard Kuster
Bernhard Kuster
Proteomics is making important contributions to drug discovery, from target deconvolution to mechanism of action (MoA) elucidation and the identification of biomarkers of drug response. Here we introduce decryptE, a proteome-wide approach that measures the full dose–response characteristics of drug-induced protein expression changes that informs cellular drug MoA. Assaying 144 clinical drugs and research compounds against 8,000 proteins resulted in more than 1 million dose–response curves that can be interactively explored online in ProteomicsDB and a custom-built Shiny App. Analysis of the collective data provided molecular explanations for known phenotypic drug effects and uncovered new aspects of the MoA of human medicines. We found that histone deacetylase inhibitors potently and strongly down-regulated the T cell receptor complex resulting in impaired human T cell activation in vitro and ex vivo. This offers a rational explanation for the efficacy of histone deacetylase inhibitors in certain lymphomas and autoimmune diseases and explains their poor performance in treating solid tumors.

1 September 1999 in Journal of Molecular Catalysis B: Enzymatic
Verified
Journal Article
Closed access
BHB Hock
B Hock
MRM Rahman
M Rahman
SRS Rauchalles
S Rauchalles
ADA Dankwardt
A Dankwardt
MSM Seifert
M Seifert
KKK Kramer
K Kramer

1 January 2010 in Journal of AOAC INTERNATIONAL
Verified
Journal Article
Open access
PDF file
CSCarolin Schüller
Carolin Schüller
JWJulia C Wiebe
Julia C Wiebe
APAntje Pegel
Antje Pegel
KKKarl Kramer
Karl Kramer
Arne SkerraArne Skerra
Arne Skerra
BHBertold Hock
Bertold Hock
Even though rabbit antibodies (Abs) are known to exceed murine Abs with respect to specificity, affinity, and stability, cloned leporid immune repertoires have been rarely considered in recombinant Ab preparation for environmental analysis. We have developed a set of four tetp/o-based phasmid vectors that allow the efficient cloning of both murine and leporid Ab repertoires. These vectors differ in the design of the cloning sites, choice of signal peptides, and antibiotic selection markers. A set of 39 primer oligodeoxynucleotides has been developed for the PCR amplification of rabbit Ab genes, representing the most exhaustive coverage of the leporid immune repertoire described so far. The atrazine-specific murine Fab fragment K411B and a cloned V-gene repertoire from sulfonamide-immunized rabbits were used to compare these phasmids with respect to expression of Fab fragments, phagemid titers, and number of Fab displaying phagemid particles. Our results show that the ratio of recombinant phagemids could be increased up to 65% of total phage titer by utilizing the appropriate phasmid. Based on this system, the selection of two sulfonamide-specific rabbit Abs, SA2 23 and SA2 90, was accomplished after a single phagemid panning round.